{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:23:14Z","timestamp":1782847394906,"version":"3.54.5"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"unspecified","delay-in-days":245,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"Abstract<\/jats:title>\n\t \n\t Background:<\/jats:title>\n\t Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression. It primarily acts through the serotonin 5-HT2A receptor but interacts with 5-HT1A and 5-HT2C receptors. Its precise mechanisms remain under investigation.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Objectives:<\/jats:title>\n\t (1) To consolidate evidence on psilocybin\u2019s efficacy and safety for depression and the role of 5HT2a, (2) to identify limitations in the literature, and (3) to highlight areas needing further research.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Methods:<\/jats:title>\n\t This systematic review follows PRISMA guidelines and analyses 22 studies, including randomised controlled trials (RCTs) and open-label studies. The studies cover various populations, including individuals with treatment-resistant depression, different dosing regimens, and adjunctive therapies.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Results:<\/jats:title>\n\t Psilocybin therapy shows substantial and rapid antidepressant effects, often after one or two sessions with psychological support. Improvements are sustained for weeks or months in many cases. Psilocybin is generally well-tolerated, with mild adverse effects such as anxiety during administration and transient headaches, which are manageable in controlled settings.<\/jats:p>\n\t <\/jats:sec>\n\t \n\t Conclusions:<\/jats:title>\n\t Psilocybin demonstrates promise as a novel treatment for depression, especially for individuals unresponsive to conventional antidepressants. Further research is needed to refine dosing, explore long-term effects, and understand its mechanisms of action.<\/jats:p>\n\t <\/jats:sec>","DOI":"10.1017\/neu.2025.10039","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:23:38Z","timestamp":1756887818000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence"],"prefix":"10.1017","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-8294","authenticated-orcid":false,"given":"Filipe Reis Teodoro","family":"Andrade","sequence":"first","affiliation":[{"name":"Central Institute of Mental Health (ZI)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Buchborn","sequence":"additional","affiliation":[{"name":"Central Institute of Mental Health (ZI)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Thalheimer","sequence":"additional","affiliation":[{"name":"Universidade Federal of Rio Grande do Sul (UFRGS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus W.","family":"Meinhardt","sequence":"additional","affiliation":[{"name":"Central Institute of Mental Health (ZI)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Joca","sequence":"additional","affiliation":[{"name":"Aarhus University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria Martins","family":"de Almeida","sequence":"additional","affiliation":[{"name":"Universidade Federal of Rio Grande do Sul (UFRGS)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,9,3]]},"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270825100392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T07:23:17Z","timestamp":1759908197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270825100392\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"alternative-id":["S0924270825100392"],"URL":"https:\/\/doi.org\/10.1017\/neu.2025.10039","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e86"}}